摘要:
Область применения: Изобретение относится к комбинаторной химии, фармации и косметологии, позволяет синтезировать новые комбинаторные библиотеки производных антибиотиков для применения в фармации, косметологии и фармации. Суть изобретения: новые комбинаторные производные антибиотиков на основе супрамолекулярных структур, отличающиеся тем, что супрамолекулярные структуры (В) получены путем комбинаторного синтеза из одной исходной молекулы полифункционального антибиотика (А1) с двумя и более доступными для ковалентной модификации группами в реакции, как минимум, с двумя разными модификаторами (М2 и М3) одновременно согласно схеме синтеза m А1+k М2 + k М3=m В, при этом образуется комбинаторная смесь модифицированных производных исходной молекулы, с максимальным разнообразием производных, а в качестве биологически активных веществ для создания фармацевтических композиций используют цельную комбинаторную смесь в виде супрамолекулярной структуры без разделения на индивидуальные компоненты, а в реакции образуется комбинаторная смесь В модифицированных производных исходной молекулы антибиотика (А1), количество комбинаций которых является максимальным (m). Технический результат: модифицированные комбинаторные производные антибиотиков с антимикробной и антигрибковой активностью в отношении мультирезистентных и полирезистентных штаммов микроорганизмов и грибов. Средства имеют широкий спектр действия, а супрамолекулярная и комбинаторная структура их десятков и сотен производных исключает привыкание микроорганизмов.
摘要:
It relates to polymyxin analogues having either a short length fatty acyl unit than polymyxin or simply there is a lack of such unit, a hydrophobic chain at the 6th amino acid position of the polymixyn analogue, and in some cases a lower cationic charge than polymyxin, as well as a disulfide bond and an amide or an ester bond in the scaffold. These polymyxin analogues are selective against Gram-negative bacteria and show a particular high antibacterial activity against P. aeruginosa resistant strains, thus they are useful in the treatment of bacterial infections. It also relates to pharmaceutical compositions comprising them.
摘要:
The present invention relates to antimicrobial compounds and their uses, and in particular to peptide antibiotics which may be used in the treatment of bacterial infections such as Gram-negative bacterial infections, particularly those caused by multidrug-resistant (MDR) pathogens.
摘要:
Described are compounds of formula (I) for use in combination treatment with a second active agent, such as rifampicin, for example for treatment of a microbial infection. The compound of formula (I) is a polymyxin compound is: where the groups -A-, -R 1 , -R 2 , -R 3 , -R 4 , -R 5 , -R 6 , -R 7 , -R 8 , and -X-are described in detail within the description.
摘要:
Disclosed herein is a composition comprising at least one polymyxin or a salt thereof represented by formula (I) wherein R 1 is an aliphatic linear or branched C 6 -C 10 acyl group, or (I') R 5 is -CH(CH 3 ) 2 , -CH 2 CH(CH 3 ) 2 , -CH(CH 3 )CH 2 CH 3 , or -CH 2 C 6 H 5 ; R 6 is -CH(CH 3 ) 2 , -CH 2 CH(CH 3 ) 2 , or -CH(CH 3 )CH 2 CH 3 ; each of R 2 , R 3 , R 4 , R 7 and R 8 is either -(CH 2 ) X CH 2 NH 2 or -(CH 2 ) x CH 2 N(CH 2 SO 3 M) 2 ; wherein x is 0 or 1; wherein M is a monovalent cation; and wherein at least three of R 2 , R 3 , R 4 , R 7 and R 8 are -(CH 2 ) x CH 2 N(CH 2 SO 3 M) 2 .
摘要:
The present invention relates to a combination comprising a polymyxin derivative of formula (I) defined herein wherein R1 is Dab; R2 is Thr; R3 is DThr; R4 is Dab; R5 is Dab; R6 is DPhe; R7 is Leu; R8 is Abu; R9 is Dab; R10 is Thr; and R(FA) is octanoyl; or wherein R1 is absent; R2 is Thr; R3 is DSer; R4 is Dab; R5 is Dab; R6 is DPhe; R7 is Leu; R8 is Dab; R9 is Dab; R10 is Thr; and R(FA) is octanoyl; or pharmaceutically acceptable salts thereof; and at least one antibiotic resistance breaker selected from the group consisting of zidovudine, suloctidil, mefloquine, phenoxybenzamine or a pharmaceutically acceptable derivative thereof. The invention also provides the use of this combination in the treatment of bacterial infections, preferably Gram-negative bacterial infections, particularly drug-resistant Gram-negative bacterial infections.
摘要:
The present invention regards a HPLC method useful for analyzing colistimethate sodium (CMS) or for the separation of CMS components. It consists in a HPLC method using a hydrophobic stationary phase and a mobile phase comprising an aqueous buffer and an organic solvent whose concentration in the mobile phase is increased during the elution. The aqueous buffer is preferably a phosphate buffer and the organic solvent preferably acetonitrile.
摘要:
The present invention relates to antimicrobial compounds and their uses, and in particular to peptide antibiotics which may be used in the treatment of bacterial infections such as Gram-negative bacterial infections, particularly those caused by multidrug-resistant (MDR) pathogens.